Expert Interview
Discussing the potential of ACELYRIN's Izokibep in psoriatic arthritis with a rheumatologist.
Ticker(s): SLRNInstitution: University of Washington
- Clinical Associate Professor in Rheumatology at the University of Washington.
- Treats 50 patients with psoriatic arthritis
- Research focuses on studying biomarkers to assess autoimmune, rheumatic diseases and developing new treatment options for inflammatory conditions refractory to current standard therapy.
What are your thoughts on the potential of anti-IL-17a antibodies in treating psoriatic arthritis?
Added By: sara_adminIs the long-term 46-week data from the Phase 2 trial of Izokibep in psoriatic arthritis encouraging?
Do you have any critiques of the Phase 2 study and what data or trial design would you want to see in a Phase 3 study for Izokibep in PsA?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
